← Human Trials & Peer-Reviewed Studies
Oxyntomodulin May Distinguish New-Onset Diabetes After Acute Pancreatitis From Type 2 Diabetes.
Plain-language guide to PMID 32463621 (2020): observational study of Oxyntomodulin, pancreatitis (after the acute phase).
Key Facts
- PMID
- 32463621
- Journal
- Clinical and translational gastroenterology
- Year
- 2020
- Study type
- Observational Study
- Authors
- Bharmal SH et al. (6 authors)
- DOI
- 10.14309/ctg.0000000000000132
What This Study Did, in Plain Language
What Was Tested
Researchers studied Oxyntomodulin in the context of pancreatitis (after the acute phase) in this observational study publication.
New-onset diabetes is an important sequela of acute pancreatitis, but there are no biomarkers to differentiate it from the much more common type 2 diabetes.
The objective was to investigate whether postprandial circulating levels of gut hormones can serve this purpose.
Who Took Part
The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.
This was a case-control study nested into a prospective longitudinal cohort study that included 42 insulin-naive cases with new-onset prediabetes/diabetes after acute pancreatitis (NODAP) and prediabetes/diabetes followed by acute pancreatitis (T2D-AP), sex matched with 21 healthy controls.
Analysis of variance and linear regression analysis were conducted in unadjusted and adjusted models (accounting for age, homeostatic model assessment of β-cell function, and magnetic resonance imaging-derived body fat composition).
How the Study Was Run
All individuals underwent a standardized mixed-meal test, and blood samples were assayed for gut hormones (glucose-dependent insulinotropic peptide, glucagon-like peptide-1, oxyntomodulin, and peptide YY).
What Was Measured
PubMed files the paper under topics including Biomarkers, Case-Control Studies, Diabetes Mellitus, Type 2, Diagnosis, Differential, Feasibility Studies, Longitudinal Studies and Oxyntomodulin.
What This Means in Plain Language
This is an observational study of Oxyntomodulin in people with pancreatitis (after the acute phase).
The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2020 (Clinical and translational gastroenterology), a journal based in United States.
More context: the Oxyntomodulin compound page, Pancreatitis (after the acute phase) research.
Our Notes on the Compound
Oxyntomodulin: A natural 37-amino-acid gut hormone that activates both GLP-1 and glucagon receptors; the model for the newer GLP-1/glucagon dual agonists.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.